论文部分内容阅读
近年来研究证实,青光眼病人的细胞免疫参数明显降低,这很可能是手术或药物治疗后,眼压虽正常,但视功能仍继续下降的原因之一。基于上述观点,出现了应用免疫调节剂综合治疗青光眼的方法。本文报道了对年龄48～73岁,经手术或药物治疗,眼压正常的进展期和晚期开角型青光眼37例72眼,采用T-碘酪蛋白(T-activin)进行治疗,并观察其效果。同时以相应年龄21名健康人作对照。病人除眼科检查外,用玫瑰花结试验测定免疫反应能力。同时测出T、
In recent years, studies have confirmed that glaucoma patients significantly reduced cellular immune parameters, which is likely to be surgery or drug treatment, although the normal intraocular pressure, but the visual function continues to decline one of the reasons. Based on the above view, the emergence of a combination of immunomodulators glaucoma treatment methods. This article reports the treatment of 37 patients and 72 eyes with advanced open-angle and open-angle glaucoma, aged 48-73 years, surgically or medically treated, and treated with T-activin. effect. At the same time, corresponding 21 healthy people as control. In addition to ophthalmic examination of the patient, the rosette test was used to measure the immune response. At the same time measured T,